foscarnet and HIV
foscarnet has been researched along with HIV in 28 studies
Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.
phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.
HIV: Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy of foscarnet on HIV infection in patients with late-stage HIV disease and multiple drug resistance." | 9.12 | Foscarnet salvage therapy for patients with late-stage HIV disease and multiple drug resistance. ( Bossi, P; Boubezari, I; Calvez, V; Canestri, A; Caumes, E; Dominguez, S; Ghosn, J; Katlama, C; Ktorza, N; Marguet, F; Wirden, M, 2006) |
| " Administration of foscarnet during two years, recommended as suppressive therapy for a previous cytomegalovirus retinitis, might have caused a sustained reduction in plasma HIV-RNA, contributing to her long-term survival." | 7.69 | [Long term survival in an HIV-immunosuppressed patient treated with foscarnet]. ( Bravo, R; González-Lahoz, J; Mas, A; Moreno, V; Soriano, V, 1996) |
| "The drug sensitivities of human immunodeficiency virus (HIV) isolates from a group of patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC) who were receiving zidovudine (3'-azido-3'-deoythymidine, AZT) therapy were tested by means of a newly developed plaque assay in CD4+ HeLa cells." | 7.67 | HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. ( Darby, G; Larder, BA; Richman, DD, 1989) |
| "The DNA polymerase of human herpes viruses, including cytomegalovirus (CMV), and the reverse transcriptase of human immunodeficiency virus (HIV) are selectively inhibited in vitro by the pyrophosphate analogue foscarnet." | 6.17 | Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. ( Bryson, HM; Wagstaff, AJ, 1994) |
| "To evaluate the efficacy of foscarnet on HIV infection in patients with late-stage HIV disease and multiple drug resistance." | 5.12 | Foscarnet salvage therapy for patients with late-stage HIV disease and multiple drug resistance. ( Bossi, P; Boubezari, I; Calvez, V; Canestri, A; Caumes, E; Dominguez, S; Ghosn, J; Katlama, C; Ktorza, N; Marguet, F; Wirden, M, 2006) |
| "Foscarnet inhibits human immunodeficiency virus (HIV) replication in vitro and decreases p24 antigenemia in patients with cytomegalovirus (CMV) retinitis." | 5.08 | Foscarnet decreases human immunodeficiency virus RNA. ( Furrer, H; Hirschel, B; Kaiser, L; Olmari, M; Perrin, L; Von Overbeck, J; Yerly, S, 1995) |
| "Foscarnet was administered by continuous intravenous infusion in 15 patients with the acquired immunodeficiency syndrome (AIDS) in an open, uncontrolled study." | 5.06 | The effect of foscarnet (phosphonoformate) on human immunodeficiency virus isolation, T-cell subsets and lymphocyte function in AIDS patients. ( Faber, V; Gaub, J; Gerstoft, J; Hofmann, B; Lernestedt, JO; Lindhardt, BO; Mathiesen, LR; Pedersen, C; Poulsen, AG; Ulrich, K, 1987) |
| "During zidovudine and stavudine treatment, HIV-1 selects several mutations (thymidine-associated mutations, TAMs) in the reverse transcriptase gene that confer high- and moderate-levels of resistance, respectively, to these nucleoside reverse transcriptase inhibitors (NRTIs)." | 4.82 | Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs). ( Goldschmidt, V; Marquet, R, 2004) |
| "Foscarnet is a pyrophosphate analogue with activity against herpesviruses, human immunodeficiency virus (HIV), and other RNA and DNA viruses." | 4.78 | Mechanism of action of foscarnet against viral polymerases. ( Crumpacker, CS, 1992) |
| " Administration of foscarnet during two years, recommended as suppressive therapy for a previous cytomegalovirus retinitis, might have caused a sustained reduction in plasma HIV-RNA, contributing to her long-term survival." | 3.69 | [Long term survival in an HIV-immunosuppressed patient treated with foscarnet]. ( Bravo, R; González-Lahoz, J; Mas, A; Moreno, V; Soriano, V, 1996) |
| "Disodium palmityl phosphonoformate, a novel lipid phosphoester of the anti HIV agent phosphonoformate (foscarnet), inhibits HIV replication in H9 cells and syncytia formation in MOLT-3 cells as effectively as foscarnet itself, as shown by dose-response data from assays for expression of p17 and p24 viral antigens and syncytia formation." | 3.68 | Lipid conjugates of antiretroviral agents. II. Disodium palmityl phosphonoformate: anti-HIV activity, physical properties, and interaction with plasma proteins. ( Bhongle, NN; Camaioni Neto, C; Piratla, RK; Sarin, PS; Steim, JM; Sun, DK; Turcotte, JG, 1990) |
| "The drug sensitivities of human immunodeficiency virus (HIV) isolates from a group of patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC) who were receiving zidovudine (3'-azido-3'-deoythymidine, AZT) therapy were tested by means of a newly developed plaque assay in CD4+ HeLa cells." | 3.67 | HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. ( Darby, G; Larder, BA; Richman, DD, 1989) |
| " It is thus difficult to formulate optimal dosing regimens on the basis of what is known of foscarnet pharmacodynamics and pharmacokinetics." | 2.38 | Clinical pharmacology: foscarnet. ( Lietman, PS, 1992) |
| " The mean peak concentration in plasma following the intravenous administration of foscarnet (90 mg/kg) was 887." | 1.30 | Pharmacokinetics and absolute bioavailability of oral foscarnet in human immunodeficiency virus-seropositive patients. ( Gazzard, BG; Higgs, CJ; Lant, AF; Martin-Munley, S; Noormohamed, FH; Youle, MS, 1998) |
| " The combined effect of ddNTPs and the pyrophosphate analog phosphonoformate (PFA) on HIV reverse transcriptase was also examined, and inhibition by PFA in combination with ddTTP or AZTTP was mutually exclusive." | 1.28 | Inhibition of human immunodeficiency virus reverse transcriptase by 2',3'-dideoxynucleoside triphosphates: template dependence, and combination with phosphonoformate. ( Cheng, YC; Starnes, MC, 1989) |
Research
Studies (28)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (46.43) | 18.7374 |
| 1990's | 12 (42.86) | 18.2507 |
| 2000's | 3 (10.71) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Schott, H | 1 |
| Hamprecht, K | 1 |
| Schott, S | 1 |
| Schott, TC | 1 |
| Schwendener, RA | 1 |
| Goldschmidt, V | 1 |
| Marquet, R | 1 |
| Canestri, A | 1 |
| Ghosn, J | 1 |
| Wirden, M | 1 |
| Marguet, F | 1 |
| Ktorza, N | 1 |
| Boubezari, I | 1 |
| Dominguez, S | 1 |
| Bossi, P | 1 |
| Caumes, E | 1 |
| Calvez, V | 1 |
| Katlama, C | 1 |
| Wagstaff, AJ | 1 |
| Bryson, HM | 1 |
| Bailey, JM | 1 |
| Lightfoote, M | 1 |
| Lillehoj, E | 1 |
| Nelson, K | 1 |
| Kaiser, L | 1 |
| Perrin, L | 1 |
| Hirschel, B | 1 |
| Furrer, H | 1 |
| Von Overbeck, J | 1 |
| Olmari, M | 1 |
| Yerly, S | 1 |
| Soriano, V | 1 |
| Mas, A | 1 |
| Bravo, R | 1 |
| Moreno, V | 1 |
| González-Lahoz, J | 1 |
| Noormohamed, FH | 1 |
| Youle, MS | 1 |
| Higgs, CJ | 1 |
| Martin-Munley, S | 1 |
| Gazzard, BG | 2 |
| Lant, AF | 1 |
| Tural, C | 1 |
| Romeu, J | 1 |
| Sirera, G | 1 |
| Andreu, D | 1 |
| Conejero, M | 1 |
| Ruiz, S | 1 |
| Jou, A | 1 |
| Bonjoch, A | 1 |
| Ruiz, L | 1 |
| Arnó, A | 1 |
| Clotet, B | 1 |
| Crumpacker, CS | 1 |
| Lietman, PS | 1 |
| Tao, P | 1 |
| Zhang, X | 1 |
| Quan, K | 1 |
| Cox, S | 1 |
| Koshida, R | 1 |
| Harmenberg, J | 1 |
| Wahren, B | 1 |
| Camaioni Neto, C | 1 |
| Steim, JM | 1 |
| Sarin, PS | 1 |
| Sun, DK | 1 |
| Bhongle, NN | 1 |
| Piratla, RK | 1 |
| Turcotte, JG | 1 |
| Snoeck, R | 1 |
| Lagneaux, L | 1 |
| Delforge, A | 1 |
| Bron, D | 1 |
| Van der Auwera, P | 1 |
| Stryckmans, P | 1 |
| Balzarini, J | 1 |
| De Clercq, E | 1 |
| Vogt, M | 1 |
| Schooley, RT | 1 |
| Hirsch, MS | 1 |
| Frank, KB | 1 |
| McKernan, PA | 1 |
| Smith, RA | 1 |
| Smee, DF | 1 |
| Wondrak, EM | 1 |
| Löwer, J | 1 |
| Kurth, R | 1 |
| Larder, BA | 1 |
| Darby, G | 1 |
| Richman, DD | 1 |
| Montefiori, DC | 1 |
| Robinson, WE | 1 |
| Mitchell, WM | 1 |
| Starnes, MC | 1 |
| Cheng, YC | 1 |
| Crowe, SM | 1 |
| McGrath, MS | 1 |
| Elbeik, T | 1 |
| Kirihara, J | 1 |
| Mills, J | 2 |
| Yarchoan, R | 1 |
| Broder, S | 1 |
| Jacobson, MA | 1 |
| Crowe, S | 1 |
| Levy, J | 1 |
| Aweeka, F | 1 |
| Gambertoglio, J | 1 |
| McManus, N | 1 |
| Bergdahl, S | 1 |
| Sönnerborg, A | 1 |
| Larsson, A | 1 |
| Strannegard, O | 1 |
| Weber, J | 1 |
| Farthing, CF | 1 |
| Dalgleish, AG | 1 |
| Clark, A | 1 |
| McClure, M | 1 |
| Chanas, A | 1 |
| Gaub, J | 1 |
| Pedersen, C | 1 |
| Poulsen, AG | 1 |
| Mathiesen, LR | 1 |
| Ulrich, K | 1 |
| Lindhardt, BO | 1 |
| Faber, V | 1 |
| Gerstoft, J | 1 |
| Hofmann, B | 1 |
| Lernestedt, JO | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Foscarnet Treatment of Serious CMV Retinitis Infection in Patients With Acquired Immunodeficiency Syndrome[NCT00000726] | Phase 1 | 53 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Reviews
5 reviews available for foscarnet and HIV
| Article | Year |
|---|---|
Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs).
Topics: Adenosine Triphosphate; DNA Primers; Drug Resistance, Multiple, Viral; Foscarnet; HIV; HIV Reverse T | 2004 |
Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.
Topics: AIDS-Related Opportunistic Infections; Cytomegalovirus; Drug Administration Schedule; Drug Interacti | 1994 |
Mechanism of action of foscarnet against viral polymerases.
Topics: Antiviral Agents; DNA-Directed RNA Polymerases; Drug Interactions; Drug Resistance, Microbial; Fosca | 1992 |
Clinical pharmacology: foscarnet.
Topics: Antiviral Agents; Foscarnet; HIV; Humans; Nucleic Acid Synthesis Inhibitors; Phosphonoacetic Acid; R | 1992 |
Progress in the development of antiviral therapy for HTLV-III-associated diseases.
Topics: Acquired Immunodeficiency Syndrome; Antimony; Antiviral Agents; Foscarnet; HIV; Humans; Phosphonoace | 1987 |
Trials
6 trials available for foscarnet and HIV
| Article | Year |
|---|---|
Foscarnet salvage therapy for patients with late-stage HIV disease and multiple drug resistance.
Topics: Adult; Aged; CD4 Lymphocyte Count; Disease Progression; Drug Resistance, Multiple, Viral; Foscarnet; | 2006 |
Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.
Topics: AIDS-Related Opportunistic Infections; Cytomegalovirus; Drug Administration Schedule; Drug Interacti | 1994 |
Foscarnet decreases human immunodeficiency virus RNA.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; CD4 Lymphocyte Count; Cyt | 1995 |
[Chemotherapy and immunoprophylaxis of HIV infection].
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Foscarnet; HIV; Huma | 1986 |
Phosphonoformate (foscarnet): a pilot study in AIDS and AIDS related complex.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; Antigens, Viral; Clinical Trials as Topic; | 1987 |
The effect of foscarnet (phosphonoformate) on human immunodeficiency virus isolation, T-cell subsets and lymphocyte function in AIDS patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antibodies, Viral; Clinical Trials as Topic; Foscarnet; H | 1987 |
Other Studies
18 other studies available for foscarnet and HIV
| Article | Year |
|---|---|
Synthesis and in vitro activities of a new antiviral duplex drug linking Zidovudine (AZT) and Foscarnet (PFA) via an octadecylglycerol residue.
Topics: Antiviral Agents; Cross-Linking Reagents; Cytomegalovirus; Drug Interactions; Foscarnet; Glyceryl Et | 2009 |
Synthesis and antiviral properties of sterol phosphonoformates.
Topics: Antiviral Agents; Cholesterol Esters; Culture Techniques; Foscarnet; HIV; Humans; Phosphonoacetic Ac | 1994 |
[Long term survival in an HIV-immunosuppressed patient treated with foscarnet].
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; CD4 Lymphocyte Count; Cytomegaloviru | 1996 |
Pharmacokinetics and absolute bioavailability of oral foscarnet in human immunodeficiency virus-seropositive patients.
Topics: Administration, Oral; Adult; Antiviral Agents; Biological Availability; Foscarnet; HIV; HIV Infectio | 1998 |
Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; CD4 Lymphocyte Count; Cytomegalovirus | 1998 |
The characterization of EIAV reverse transcriptase and its inhibition by 5'-triphosphates of 2'-deoxyuridine analogs, PFA and PAA.
Topics: Antiviral Agents; Dideoxynucleotides; Foscarnet; HIV; Infectious Anemia Virus, Equine; Phosphonoacet | 1990 |
Synergistic combinations and peptides in the inhibition of human immunodeficiency virus.
Topics: Alpha-Globulins; Amino Acid Sequence; Antiviral Agents; Cell Line; Dideoxynucleosides; Drug Synergis | 1991 |
Lipid conjugates of antiretroviral agents. II. Disodium palmityl phosphonoformate: anti-HIV activity, physical properties, and interaction with plasma proteins.
Topics: Antiviral Agents; Cell Fusion; Cell Line; Chemical Phenomena; Chemistry, Physical; Foscarnet; HIV; I | 1990 |
Inhibitory effects of potent inhibitors of human immunodeficiency virus and cytomegalovirus on the growth of human granulocyte-macrophage progenitor cells in vitro.
Topics: Adenine; Adult; Antiviral Agents; Bone Marrow; Bone Marrow Cells; Cells, Cultured; Cidofovir; Cytome | 1990 |
Visna virus as an in vitro model for human immunodeficiency virus and inhibition by ribavirin, phosphonoformate, and 2',3'-dideoxynucleosides.
Topics: Antimetabolites; Antiviral Agents; Deoxyribonucleosides; Deoxyribonucleotides; Foscarnet; HIV; Organ | 1987 |
Inhibition of HIV-1 RNA-dependent DNA polymerase and cellular DNA polymerases alpha, beta and gamma by phosphonoformic acid and other drugs.
Topics: Antiviral Agents; DNA Polymerase I; DNA Polymerase II; DNA Polymerase III; Foscarnet; HIV; In Vitro | 1988 |
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; Dideoxynucleosides; Drug Resistance; Fosca | 1989 |
In vitro evaluation of mismatched double-stranded RNA (ampligen) for combination therapy in the treatment of acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Alkaloids; Amphotericin B; Antiviral Agents; Drug Therapy, Combi | 1989 |
Inhibition of human immunodeficiency virus reverse transcriptase by 2',3'-dideoxynucleoside triphosphates: template dependence, and combination with phosphonoformate.
Topics: Acquired Immunodeficiency Syndrome; Dideoxynucleosides; Dinucleoside Phosphates; DNA Replication; DN | 1989 |
Comparative assessment of antiretrovirals in human monocyte-macrophages and lymphoid cell lines acutely and chronically infected with the human immunodeficiency virus.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Foscarnet; Gene Products, gag; HIV; HIV Antigens | 1989 |
Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; HIV; HI | 1988 |
Declining levels of HIV P24 antigen in serum during treatment with foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Antigens, Viral; Antiviral Agents; Foscarnet; HIV; HIV Antigens; | 1988 |
AIDS: the virus, antivirals and vaccines.
Topics: Acquired Immunodeficiency Syndrome; Antimony; Antiviral Agents; Foscarnet; Genes, Viral; HIV; Humans | 1987 |